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This study aimed to investigate the risk and prognosis of Alzheimer’s disease (AD) and
vascular dementia (VaD) in patients with insomnia using the National Health Insurance
Service database covering the entire population of the Republic of Korea from 2007 to
2014. In total, 2,796,871 patients aged 40 years or older with insomnia were enrolled,
and 5,593,742 controls were matched using a Greedy digit match algorithm. Mortality
and the rate of admission to a long-term care facility were estimated using multivariable
Cox analysis. Of all patients with insomnia, 138,270 (4.94%) and 26,706 (0.96%) were
newly diagnosed with AD and VaD, respectively. The incidence rate ratios for AD and VaD
were 1.73 and 2.10, respectively, in patients with insomnia compared with those without.
Higher mortality rates and long-term care facility admission rates were also observed
in patients with dementia in the insomnia group. Known cardiovascular risk factors
showed interactions with the effects of insomnia on the risk of AD and VaD. However,
the effects of insomnia on the incidence of AD and VaD were consistent between the
groups with and without cardiovascular risk factors. Insomnia is a medically modifiable
and policy-accessible risk factor and prognostic marker of AD and VaD.
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INTRODUCTION
Dementia is a progressive neurodegenerative disorder characterized by impairment in cognition
that interferes with daily life activities (1). Alzheimer’s disease (AD) and vascular dementia (VaD)
are themost prevalent causes of dementia (2). Dementia is a burden on both patients and caregivers,
and also increases the global socioeconomic burden (3). To effectively counter these burdens, a
number of national policies have focused on the management and prevention of the risk factors
associated with dementia.
Insomnia is characterized by difficulty in sleep initiation or maintenance with compromised
daytime function (4). Insomnia has been reported to be related to the pathologic hallmark proteins
of AD, amyloid-β (Aβ). Deposition of Aβ was caused by inhibition of clearance pathway, and
increased synaptic activity that facilitate the accumulation of Aβ (5, 6). In positron-emission
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tomography (PET) imaging study, poor quality of sleep was
associated with a greater cortical Aβ burden in cognitively normal
elderly (7, 8). Furthermore, insomnia was associated with the
cerebrovascular disease that increase the risk of VaD through
disrupting subcortical circuits, which are related to the sleep
cycle (9–11).
Recently, two studies conducted in Taiwan investigated the
relationship between the incidence of insomnia and dementia
using data sampled from national medical records and found
a higher risk of dementia in patients with insomnia (12, 13).
However, despite the large cohort sizes of over 50,000 patients
with insomnia in these studies, analyses of population data
samples may be limited by sampling bias or systematic errors
(14). In addition, while several studies have investigated the
risk of dementia in patients with insomnia, to the best of our
knowledge, only a limited number of studies have investigated
the effect of insomnia on the prognosis of dementia.
In this study, the effects of insomnia on incident AD and
VaD were investigated using a large dataset encompassing the
medical records of the entire national population of the Republic
of Korea. The prognosis of AD and VaD were ascertained
by comparing mortality records and long-term care facility
admission records between patients with insomnia and those
without insomnia. Finally, the association between insomnia and
known cardiovascular risks was analyzed to establish the direct
effects of insomnia on AD and VaD incidence.
MATERIALS AND METHODS
Participants
This study was a retrospective nationwide population-based
cohort study, using data from a national health insurance claims
database established by the National Health Insurance Service
(NHIS) of Korea. The NHIS is a mandatory health insurance
system in the Republic of Korea, which encompassed 97.3% (52
million) of the Korean population, as of 2015. Since the adoption
of the fee-for-service model by the NHIS to pay healthcare
providers, additional information such as the history of diagnosis
codes, details of medical bills, drug prescription and procedures,
and demographic records have been compiled. Health Insurance
Review Agency (HIRA) provides a quality control role and
evaluates healthcare performance and reviews medical data (15).
This database is provided by the “Big Data Steering Department”
of the NHIS for research purposes and encompasses information
on the entire Korean population. Further details regarding this
database have been provided previously (16).
We defined the diagnoses of insomnia, AD, and VaD using
the tenth revision of the International Statistical Classification
of Diseases (ICD-10) codes recorded in the NHIS database.
Individuals were defined as having insomnia if the code G47.0
(disorders of initiating and maintaining sleep) was recorded in
the NHIS database. The diagnosis of AD was defined by having
the code F00 (Dementia in Alzheimer disease) or G30 (Alzheimer
disease) in the NHIS database. The diagnosis of VaD was
defined by having the code F01 (Vascular dementia). The date of
dementia diagnosis was defined as the date when the prescription
of an anti-dementia medication and registration of a dementia
code coincided. The diagnostic criteria for dementia based on
ICD-10 codes have been reported in previous studies (17, 18).
Among the entire national population, 8,080,619 patients
diagnosed with insomnia between 2007 and 2014 were included
in this study. A total of 4,196,414 patients and 254,806
patients who were initially diagnosed with insomnia and
dementia, respectively, before 2007 were excluded, and 832,528
patients aged < 40 years were excluded. Following this,
the insomnia group included 2,796,871 patients (Figure 1).
We used the propensity score analysis to generate the
age- and sex- matching control group. The demographic
confounders (low income, and place of residence), and
medical histories (hypertension, diabetes mellitus, dyslipidemia,
congestive heart failure, ischemic heart disease, atrial fibrillation,
chronic obstructive pulmonary disease, and ischemic stroke)
were adjusted in the analysis. Finally, 1:2 matching without
replacements was conducted using a Greedy digit match
algorithm, yielding 5,593,742 individuals in the non-insomnia
group. For all participants, the number of AD and VaD diagnoses
as well as information on mortality and long-term care facility
admission were analyzed.
This study was approved by the NHIS inquiry commission
and the institutional review board of Gangnam Severance
Hospital (IRB-No 3-2016-0307). The requirement for informed
consent was waived by institutional review board which approved
the study. The privacy of each participant was protected by de-
identification of the national insurance claims data for analysis.
All research was performed in accordance with the relevant
guidelines and regulations.
Definition
Patients with hypertension were indicated when anti-
hypertensive medications were prescribed with ICD-10
codes of I10 (essential hypertension), I13 (hypertensive
heart and renal disease), or I15 (secondary hypertension).
Patients were defined as having type 2 diabetes if anti-diabetic
drugs (insulins, sulfonylureas, metformin, meglitinides,
thiazolidinediones, dipeptidyl peptidase-4 inhibitors, and
α-glucosidase inhibitors) were prescribed with ICD-10
codes of E11 (non-insulin-dependent diabetes mellitus),
E12 (malnutrition-related diabetes mellitus), E13 (other specified
diabetes mellitus), or E14 (unspecified diabetes mellitus).
Patients were defined as having dyslipidemia by the presence of
the ICD-10 code E78 (disorders of lipoprotein metabolism and
other lipidemias).
The ICD-10 codes used for other cardiovascular risks
were as follows. The ICD-10 codes for ischemic heart disease
(IHD) are I20 (angina pectoris), I21 (ST elevation and non-
ST elevation myocardial infarction), I22 (subsequent ST
elevation and non-ST elevation myocardial infarction), I23
(current complications following ST elevation and non-ST
elevation myocardial infarction), I24 (other acute ischemic
heart diseases), and I25 (chronic ischemic heart disease);
for stroke, the ICD-10 codes are I63 (cerebral infarction)
and I64 (stroke, not specified as hemorrhage or infarction);
for atrial fibrillation (AF), the ICD-10 code is I48.0 (atrial
fibrillation and flutter); for congestive heart failure (CHF),
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FIGURE 1 | Flowchart of the study design.
the ICD-10 code is I50.0 (congestive heart failure); and for
chronic obstructive pulmonary disease, (COPD) the ICD-10
codes are J41 (simple and mucopurulent chronic bronchitis),
J42 (unspecified chronic bronchitis), J43 (emphysema), and
J44 (other chronic obstructive pulmonary disease). The
detailed list of ICD-10 codes for diagnoses is presented in
Supplementary Table 1.
Statistical Analysis
For acquiring the propensity score-matched cohort, categorical
and continuous variables were compared using the McNemar’s
test and paired t-test, respectively. The cumulative event
rates were compared between the insomnia and non-insomnia
groups based on Kaplan-Meier censoring estimates, using
the log-rank test. Crude risks were analyzed in the overall
cohort, and the adjusted incidence rate ratio (IRR) was
subsequently estimated based on the results of multivariable
Cox regression analyses after adjustment for age and sex.
Statistical analyses were performed using SAS version 9.3
(SAS Institute, Cary, North Carolina, USA), Stata statistical
software, release 12 (StataCorp, College Station, Texas, USA),




The baseline characteristics of participants are presented in
Table 1. The numbers of individuals in the insomnia and non-
insomnia groups were 2,796,871 and 5,593,742, respectively.
The mean age was 59.48 years, and 37.69% were male in
both groups. The proportions of cardiovascular risks factors,
such as diabetes mellitus, hypertension, dyslipidemia, stroke,




Number of patient-years 26,305,394 12,319,096
Age (years) 59.48 ± 11.82 59.48 ± 11.82
Male (%) 2,108,552 (37.7) 1,054,276 (37.7)
Diabetes mellitus (%) 596,889 (10.7) 421,342 (15.1)
Hypertension (%) 1,664,606 (29.8) 1,106,869 (39.6)
Dyslipidemia (%) 870,731 (15.6) 643,958 (23.0)
Stroke (%) 21,738 (0.4) 50,348 (1.8)
Ischemic heart disease (%) 426,884 (7.6) 415,221 (14.9)
Congestive heart failure (%) 20,226 (0.4) 44,209 (1.6)
Atrial fibrillation (%) 51,944 (0.9) 54,172 (1.9)
Chronic obstructive pulmonary disease (%) 439,469 (7.9) 434,583 (15.5)
Data are presented as mean ± SD or number (percentage).
IHD, CHF, AF, and COPD were higher in the insomnia group
(Table 1).
Incidence Rates of Alzheimer’s Disease
and Vascular Dementia in Patients With
Insomnia
Of the 5,593,742 individuals in the non-insomnia group, 160,660
(2.87%) and 25,058 (0.45%) individuals were newly diagnosed
with AD and VaD during 26,305,394 person-years, respectively.
The crude incidence rate was 6.11 per 1,000 person-years for
AD and 0.95 per 1,000 person-years for VaD. In the insomnia
group, 138,270 (4.94%) and 26,706 (0.96%) individuals were
correspondingly diagnosed with AD and VaD during 12,319,096
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TABLE 2 | Incidence rate of dementia in the insomnia and non-insomnia groups.
Alzheimer’s disease Vascular dementia
Insomnia N Events Person-Years Crude IR† IRR (95% CI)‡ Events Person-Years Crude IR† IRR (95% CI)‡
Total No 5,593,742 160,660 26,305,394 6.11 1 (ref.) 25,058 26,305,394 0.95 1 (ref.)
Yes 2,796,871 138,270 12,319,096 11.22 1.73 (1.72, 1.75) 26,706 12,319,096 2.17 2.10 (2.06, 2.14)
Sex
Male No 2,108,552 45,049 9,577,665 4.70 1 (ref.) 8,575 9,577,665 0.90 1 (ref.)
Yes 1,054,276 43,302 4,324,631 10.01 1.99 (1.96, 2.01) 10,779 4,324,631 2.49 2.53 (2.46, 2.61)
Female No 3,485,190 115,611 16,727,729 6.91 1 (ref.) 16,483 16,727,729 0.99 1 (ref.)
Yes 1,742,595 94,968 7,994,465 11.88 1.63 (1.61, 1.64) 15,927 7,994,465 1.99 1.88 (1.84, 1.93)
Age
40–49 No 1,342,522 670 6,733,805 0.10 1 (ref.) 365 6,733,805 0.05 1 (ref.)
Yes 671,261 1,585 3,282,546 0.48 4.64 (4.24, 5.08) 987 3,282,546 0.30 5.03 (4.45, 5.68)
50–59 No 1,616,552 4,458 7,655,274 0.58 1 (ref.) 1,415 7,655,274 0.19 1 (ref.)
Yes 808,276 7,017 3,688,638 1.90 3.12 (3.00, 3.24) 2,843 3,688,638 0.77 3.84 (3.60, 4.10)
60–69 No 1,354,602 30,120 6,545,914 4.60 1 (ref.) 5,941 6,545,914 0.91 1 (ref.)
Yes 677,301 31,835 3,049,836 10.44 2.19 (2.16, 2.23) 7,130 3,049,836 2.34 2.43 (2.34, 2.51)
70–79 No 994,826 81,522 4,363,196 18.68 1 (ref.) 12,352 4,363,196 2.83 1 (ref.)
Yes 497,413 65,928 1,905,019 34.61 1.77 (1.75, 1.79) 11,438 1,905,019 6.00 1.97 (1.92, 2.02)
80–89 No 262,792 40,836 947,601 43.10 1 (ref.) 4,735 947,601 5.00 1 (ref.)
Yes 131,396 29,458 372,652 79.05 1.65 (1.63, 1.68) 4,027 372,652 10.81 1.92 (1.84, 2.01)
>90 No 22,448 3,054 59,605 51.24 1 (ref.) 250 59,605 4.20 1 (ref.)
Yes 11,224 2,447 20,405 119.92 1.86 (1.75, 1.97) 281 20,405 13.77 2.56 (2.13, 3.07)
†
Crude incidence rate of dementia per 1,000 person-years.
‡ Incidence rate ratio adjusted for age and sex.
IR, incidence rate; IRR, incidence rate ratio; CI, confidence interval; ref, reference.
person-years, respectively. The crude incidence rates of AD and
VaD were 11.22 per 1,000 person-years and 2.17 per 1,000
person-years, respectively (Table 2).
The IRRs of AD and VaD in the insomnia group were 1.73
(1.72–1.75, 95% CI) and 2.10 (2.06–2.14, 95% CI), respectively
(Table 2). Higher IRR values for AD and VaD were observed
in men than in women, and the younger age group tended to
show higher IRRs for AD and VaD. However, the IRR in those
aged ≥90 years was higher than that in those in their 80s. The
cumulative incidence changes also showed the higher incidence
of AD and VaD in the insomnia group (Figure 2).
Long-Term Care Facility Admission and
Mortality in the Insomnia and
Non-insomnia Groups
Among patients with AD in the insomnia group, the rate
of admission to long-term care facilities was 26.6 per 1,000
person-years, a value 1.2-fold higher than that in patients
with AD in the non-insomnia group. Among patients with
VaD in the insomnia group, 26.3 patients per 1,000 person-
years were admitted to long-term care facilities, and the
age- and sex-adjusted hazard ratio was 1.21 compared to the
patients with VaD in the non-insomnia group (Table 3). In
addition, patients with AD and VaD in the insomnia group
had higher mortality rates than those in the non-insomnia
group (Table 3).
Interaction of Insomnia With the
Cardiovascular Risks
The IRR of AD in the insomnia group was lower in patients
with underlying cardiovascular risks, such as diabetes mellitus,
dyslipidemia, stroke, IHD, CHF, AF, and COPD than in those
without. These cardiovascular risk factors showed interactions
with the effects of insomnia on the risk of AD (interaction
P < 0.001, Table 4). However, the IRRs of AD in patients with
or without cardiovascular risks were still higher than those in
the non-insomnia groups (IRR > 1.0, Table 4). In the VaD
patients with insomnia, diabetes mellitus, stroke, IHD, and CHF
showed an interaction with the effects of insomnia on the risk of
VaD (Table 4).
DISCUSSION
In this study using medical data of the national population, both
incidence rates and changes in the cumulative incidence of AD
and VaD were found to be greater in individuals with insomnia
than in those without. Moreover, worse prognosis was observed
in patients with AD or VaD in the insomnia group with regard to
higher rates of admission to long-term care facilities and higher
mortality rates.
The role of sleep in the accumulation of Aβ has been
identified in previous studies (19, 20). In amyloid precursor
protein transgenic (Tg2576) mice, the Aβ burden in the cerebral
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FIGURE 2 | Kaplan-Meier curves of the incidence probability of Alzheimer’s disease (A) and vascular dementia (B) in the insomnia group (red) and non-insomnia
group (black). A wash-out period of 6 months was used to minimize the possibility of reverse-causality. Therefore, time “0” was set as the time point 6 months after
insomnia diagnosis.
TABLE 3 | Rates of long-term care facility admission and mortality from dementia in the insomnia and non-insomnia groups.
Insomnia Admission rate (/1,000
person-years)
Adjusted HR (95% CI) Mortality rate (/1,000
person-years)
Adjusted HR (95% CI)
Alzheimer’s disease No 21.0 1 (ref.) 129.3 1 (ref.)
Yes 26.6 1.24 (1.21, 1.28) 133.5 1.07 (1.04, 1.10)
Vascular dementia No 21.2 1 (ref.) 131.4 1 (ref.)
Yes 26.3 1.21 (1.13, 1.30) 128.2 1.08 (1.01, 1.15)
HR, Hazard ratio; CI, confidence interval; ref, reference.
interstitial fluid decreased during sleep; however, it increased
while waking. This fluctuation in the levels of cerebrospinal
fluid Aβ was also observed in humans (21). Previous PET
studies showed that poorer quality of sleep was associated
with a greater cortical Aβ burden in cognitively normal elderly
(7, 8). Moreover, insomnia could be associated with an increase
in the level of the sleep cycle-related hormone, orexin, and
a systemic inflammation process through the activation of
microglial cells, thereby resulting in Aβ accumulation (21, 22).
Previously, a 1.2- to 2.3-fold increase in the risk of AD in patients
with insomnia has been reported by both community-based
and institutional cohort studies (23–25). Our findings using
nationwide population data support the findings of previous
studies; we reported a 1.7-fold higher IRR of AD in patients
with insomnia. In addition, the cumulative incidence of AD
was higher among patients with insomnia than among those
without insomnia (Figure 2). In both the insomnia and non-
insomnia groups, women showed a higher crude incidence rate
of AD (Table 2). However, the IRRs of AD in patients with
insomnia were higher in men than in women suggesting that
insomniamay have a stronger effect on AD inmen. Differences in
sleeping patterns with respect to sex, especially an increase in the
frequency of sleep apnea, may modulate the susceptibility to the
effects of insomnia (26, 27). Furthermore, differences in orexin
expression and sensitivity to the hormone, as suggested in animal
studies, could explain the sex differences in the effect of insomnia
on AD pathophysiology (28, 29).
Imaging studies have previously shown that insomnia is
directly associated with the brain imaging biomarkers of VaD,
such as white matter lesions and cerebral microbleeds (9–11).
Changes in cerebral blood perfusion and systemic inflammation
due to insomnia may promote small vessel disease and ischemic
stroke, thereby increasing the risk of VaD (30–34). Although
previous studies have observed trends for a higher risk of VaD
in patients with insomnia, these were not statistically significant,
possibly due to the small sample sizes (25, 35). However, an
∼2-fold higher incidence of VaD in patients with insomnia
was observed in the current study using nationwide population
data. The interaction with underlying cardiovascular risks may
have affected the results. Table 4 showed the interactions of the
cardiovascular risks with the incidence of AD and VaD. The
lower IRR in those with cardiovascular risk factors than in those
Frontiers in Neurology | www.frontiersin.org 5 May 2021 | Volume 12 | Article 611446
Baek et al. Effects of Insomnia on Dementia
TABLE 4 | Subgroup analysis for dementia risk in patients with insomnia.
Alzheimer’s disease Vascular dementia
IRR Lower Upper Interaction P IRR Lower Upper Interaction P
DM 1.59 1.56 1.61 < 0.001 1.81 1.75 1.88 <0.001
Without DM 1.70 1.68 1.71 2.07 2.03 2.11
HTN 1.59 1.57 1.60 0.371 1.90 1.85 1.94 0.057
Without HTN 1.57 1.55 1.59 1.84 1.78 1.89
Dyslipidemia 1.61 1.59 1.64 <0.001 1.99 1.92 2.06 0.488
Without dyslipidemia 1.71 1.70 1.73 2.01 1.97 2.06
Stroke 1.18 1.13 1.24 <0.001 1.48 1.38 1.58 <0.001
Without stroke 1.69 1.67 1.70 1.92 1.88 1.96
IHD 1.56 1.53 1.58 <0.001 1.80 1.74 1.88 <0.001
Without IHD 1.64 1.62 1.65 1.98 1.94 2.02
CHF 1.24 1.18 1.31 <0.001 1.53 1.36 1.73 <0.001
Without CHF 1.70 1.69 1.71 2.05 2.02 2.09
AF 1.53 1.47 1.60 <0.001 1.96 1.80 2.13 0.734
Without AF 1.72 1.70 1.73 2.06 2.02 2.09
COPD 1.58 1.56 1.61 <0.001 1.91 1.83 1.99 0.116
Without COPD 1.64 1.62 1.65 2.00 1.96 2.04
The Incidence rate ratio (IRR) of Alzheimer’s disease (A) and vascular dementia (B) in subgroups with vascular risk factors are shown with 95% confidence interval. The effects of insomnia
on the risk of dementia were weaker in subgroups with well-known cardiovascular risk factors than those without.
IRR, incidence rate ratio; DM, diabetes mellitus; HTN, hypertension, IHD, ischemic heart disease; CHF, congestive heart failure; AF, Atrial fibrillation; COPD, Chronic obstructive pulmonary
disease; CI, confidence interval.
without reflected the relatively smaller effect of insomnia on the
incidence of dementia. However, consistently high IRR (>1.0)
of the insomnia patients with the cardiovascular risks suggested
that the effects of insomnia on the incidence of dementia is
considerable, irrespective of the coexistence of cardiovascular
risks (Table 4). Therefore, the effects of insomnia on the incident
dementia in the patients with cardiovascular risks should not be
overlooked in the clinical situations.
In addition to its effect on the incidence of AD and VaD,
insomnia also influences the prognosis following dementia
diagnosis. The major outcome events of dementia were expressed
in terms of the rate of admission to a long-term care facility
and mortality rate (36–38). In elderly people, the presence of
insomnia increased the risk of long-term care facility admission
due to higher occurrence of behavioral and psychological
symptoms as well as burden on caregivers (39). Higher mortality
and rates of admission to long-term care facilities suggest
that worse prognosis can be expected in patients with pre-
existing insomnia at the time of dementia diagnosis. Moreover,
further investigations are required to confirm the possible
modification of the dementia prognosis by clinical interventions
for insomnia.
This study has several limitations. First, this is a retrospective
analysis. Therefore, the results are particularly susceptible to
the effects of reverse causality bias. To overcome this issue, we
limited the participants to the newly diagnosed insomnia patients
after 2007, and we collected data on dementia diagnosis at least
6 months after the diagnosis of insomnia for the cumulative
incidence analysis tominimize bias (Figure 2). Second, dementia,
insomnia, and cardiovascular risks were diagnosed based on
diagnostic codes without the evaluation of medical history
or neuropsychological tests. The patients who suffered from
insomnia may not visit clinics or hospitals. There are also
possible misdiagnoses of insomnia in the patients having major
psychiatric diseases. Therefore, the incidence of insomnia could
be underestimated or overestimated to the actual levels. Although
alcohol consumption, smoking and obesity are reported as
modifiable and important cardiovascular risks (40, 41), these
information were limited in NHIS database. Thus, there could
be possible discrepancies with regard to diagnosis, cardiovascular
risks and medication between the real-world situation and the
claims database. Also, diagnosis of mixed dementia (AD +
VaD), which accounts for a significant portion of dementia
cases showing multifactorial features, was not accessed. This is
an inevitable limitation of research using big databases with
diagnostic codes. Lastly, the effects of medication used by patients
with insomnia was not considered in this study, although the
relationship between medication use and the incident dementia
is unclear. Exposure to benzodiazepines was reported to increase
the risk of dementia (42, 43), while a recent study found that
the results were related to reverse causality and confounders
(44). One study showed no correlation between antidepressants
use and the risk of dementia (45). Moreover, the other study
found the effect of selective serotonin-reuptake inhibitor (SSRI)
treatment on the delayed progression in AD (46). In addition,
antihistamines in previous showed low association with the risk
of dementia (47, 48). Therefore, further longitudinal analysis
betweenmedication user and non-user in the national population
would clarify the effect of medication on the risk of dementia.
In conclusion, insomnia increases the incidence of AD and
VaD, and it may have effects on the prognosis of dementia. As
it is a medically modifiable and policy-accessible risk factor of
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dementia, effective strategies for insomnia may be a manageable
target for preventing dementia.
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